Plain-English translation of NCT06075771 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This 8-week study is testing whether Sinemet (a medication containing levodopa and carbidopa that increases dopamine in the brain) can help people with depression who have high inflammation markers and struggle to experience pleasure or joy. About 70 people will receive either the medication or a placebo pill, and researchers will use brain scans and other tests to see if the treatment works better than placebo.
Many people with depression don't respond well to standard antidepressants, and some who do respond still struggle with the inability to feel pleasure. This study explores whether boosting dopamine in a new way could help this specific group of patients who have signs of inflammation in their bodies.
You likely qualify if…
You likely don't qualify if…
You would take one pill per day for 8 weeks (either the study medication or placebo), with the dose potentially increasing after 4 weeks if you don't show improvement. You'll attend several visits over 10–12 weeks total for blood tests, psychiatric check-ins, brain scans (MRI), and tasks that measure your mood and motivation. The study is double-blind, meaning neither you nor the researchers will know whether you're receiving the actual medication or placebo.
AI-generated summary from trial data · Jul 14, 2026 · Not medical advice
United States